Olanzapine

Drug Profile

Olanzapine

Alternative Names: LY 170053; LY-170052; Midax; Olanzapine controlled-release; Olanzapine LAI; Olanzapine long-acting; Olanzapine pamoate; Zypadhera; Zyprexa; Zyprexa Relprevv; Zyprexa Velotab; Zyprexa Zydis

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antipsychotics; Benzodiazepines; Oxazepines; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aggression; Bipolar depression; Bipolar disorders; Manic episodes; Schizophrenia
  • Phase III Major depressive disorder
  • Clinical Phase Unknown Huntington's disease
  • No development reported Anorexia nervosa; Personality disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Feb 2016 Eli Lilly terminates a phase III trial in Major depressive disorder (Treatment-resistant, Combination therapy) in China due to lack of efficacy in interim results (NCT01687478)
  • 03 Mar 2015 No recent reports on development identified - Phase-III for Bipolar depression in China and South Korea (PO, tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top